755 related articles for article (PubMed ID: 29260623)
1. PD-1/PD-L1 in disease.
Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
3. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
4. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
7. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois.
Haeryfar SMM; Schell TD
Cancer Immunol Immunother; 2018 Nov; 67(11):1669-1672. PubMed ID: 30132082
[TBL] [Abstract][Full Text] [Related]
9. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
10. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
15. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
16. Regulatory mechanisms of PD-L1 expression in cancer cells.
Shi Y
Cancer Immunol Immunother; 2018 Oct; 67(10):1481-1489. PubMed ID: 30120503
[TBL] [Abstract][Full Text] [Related]
17. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
20. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
[Next] [New Search]
